Skip to main content

Table 4 Base case results from the healthcare perspective and patient perspective (unit: RMB)

From: Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis

Healthcare perspective
 Drug + ADT costs¥130,786¥1,230,951(¥1,100,165)
 Medical costs¥29,098¥31,339(¥2,241)
 AE costs¥266¥1,459(¥1,193)
 2nd-line Tx costs¥239,694¥23,152¥216,542
 Cost saving
Patient perspective
 Drug + ADT costs¥27,611¥307,738(¥280,127)
 Medical costs¥6,459¥7,835(¥1,376)
 AE costs¥40¥365(¥325)
 2nd-line Tx costs¥59,091¥3,473¥55,618
 Cost saving